These 20 women are 2018's Fiercest in the life sciences industry.
Read 2018's Fiercest Women in Life Sciences report!
In this week's EuroBiotech Report, AC Immune lands Lilly deal, AstraZeneca’s tremelimumab fails again and Novo inks diabetes deal.
In our EuroBiotech roundup this week, Affimed eyes accelerated approval, Evox gets Gates funding and ex-Rigontec CEO lands new gig.
In 1848, the most famous Gold Rush in American history began at Sutter's Mill near present-day Coloma, California, shaping the US economic map forever. In…
The trial found the histamine type 4 receptor antagonist had no effect on vigilance and cognitive performance.
The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.
EVERSANA delivers a fully-integrated service portfolio to help life science leaders create value for key constituents across the product lifecycle.
UCSF researchers have modified CRISPR gene editing to increase the activity of genes that create the feeling of being full.
Mission Bio will expand its reach into expand its reach into solid tumors and CRISPR applications.
The Harvard researcher who first discovered the "exercise hormone" irisin reports it may be useful in bone formation.
Sunovion and PsychoGenics unveiled positive phase 2 results for a new schizophrenia treatment that does not bind to the brain’s dopamine receptors.
Amag Pharma has struck a merger deal with Perosphere, adding an anticoagulant reversal agent in midstage trials to its emerging hematology business.
Applied Genetic Technologies’ $1 billion-plus gene therapy pact with Biogen has been torn up after their lead candidate failed a phase 1/2 trial.
